StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

TG Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $17.88M. For fiscal 2025 it was -$24.77M. The highest annual figure on record is -$86.58K in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.77M–
FY2024Dec 31, 2024-$40.52M–
FY2023Dec 31, 2023-$31.41M–
FY2022Dec 31, 2022-$176.17M–
FY2021Dec 31, 2021-$295.63M–
FY2020Dec 31, 2020-$214.51M–
FY2019Dec 31, 2019-$132.81M–
FY2018Dec 31, 2018-$128.93M–
FY2017Dec 31, 2017-$93.76M–
FY2016Dec 31, 2016-$61.59M–
FY2015Dec 31, 2015-$44.69M–
FY2014Dec 31, 2014-$35.06M–
FY2013Dec 31, 2013-$10.74M–
FY2012Dec 31, 2012-$5.19M–
FY2011Dec 31, 2011-$86.58K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.26M+428.0%
Q1 FY2026Mar 31, 2026-$17.89M–
Q4 FY2025Dec 31, 2025$19.66M–
Q3 FY2025Sep 30, 2025-$23.15M–
Q2 FY2025Jun 30, 2025$7.44M+34.3%
Q1 FY2025Mar 31, 2025-$28.72M–
Q4 FY2024Dec 31, 2024-$25.64M–
Q3 FY2024Sep 30, 2024-$12.21M-114.6%
Q2 FY2024Jun 30, 2024$5.54M–
Q1 FY2024Mar 31, 2024-$8.21M–
Q4 FY2023Dec 31, 2023-$13.21M–
Q3 FY2023Sep 30, 2023$83.70M–
Q2 FY2023Jun 30, 2023-$42.01M–
Q1 FY2023Mar 31, 2023-$59.90M–
Q4 FY2022Dec 31, 2022-$23.87M–
Q3 FY2022Sep 30, 2022-$34.50M–
Q2 FY2022Jun 30, 2022-$49.12M–
Q1 FY2022Mar 31, 2022-$68.69M–
Q4 FY2021Dec 31, 2021-$86.91M–
Q3 FY2021Sep 30, 2021-$67.20M–
Q2 FY2021Jun 30, 2021-$60.17M–
Q1 FY2021Mar 31, 2021-$81.36M–
Q4 FY2020Dec 31, 2020-$52.03M–
Q3 FY2020Sep 30, 2020-$56.53M–
Q2 FY2020Jun 30, 2020-$43.83M–
Q1 FY2020Mar 31, 2020-$62.12M–
Q4 FY2019Dec 31, 2019-$30.39M–
Q3 FY2019Sep 30, 2019-$33.20M–
Q2 FY2019Jun 30, 2019-$35.86M–
Q1 FY2019Mar 31, 2019-$33.35M–
Q4 FY2018Dec 31, 2018-$33.69M–
Q3 FY2018Sep 30, 2018-$33.01M–
Q2 FY2018Jun 30, 2018-$34.18M–
Q1 FY2018Mar 31, 2018-$28.04M–
Q4 FY2017Dec 31, 2017-$21.86M–
Q3 FY2017Sep 30, 2017-$22.78M–
Q2 FY2017Jun 30, 2017-$26.83M–
Q1 FY2017Mar 31, 2017-$22.30M–
Q4 FY2016Dec 31, 2016-$17.02M–
Q3 FY2016Sep 30, 2016-$15.04M–

More TG Therapeutics figures

See a number that looks wrong?